| Date | Title | Description |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 15.12.2025 | uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials | On behalf of the Critical Path Institute (C-Path) Florence Mowlem PhD, led this much-needed project, providing 10 best practices for EDeD design and implementation to support clinical trial data capture, along with co-authors from Top 10 ph... |
| 25.08.2025 | Harbour BioMed Appoints Yajie Li as Chief Medical Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 13.08.2025 | KBP's Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration | SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temp... |
| 13.03.2025 | bl interview. Incentives for phase 1 clinical trials, cost advantage will help India to tap global opportunity: Parexel India MD Sanjay Vyas | Pharmaceutical industry in India is now looking beyond opportunities in the generics space and focusing on new avenues including biosimilars, contract manufacturing. India’s skillsets in R&D and diverse demography makes it a promising m... |
| 05.03.2025 | Parexel Announces Updates to Board of Directors | Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs Healthcare Private Equity Investing, joins as new Director.
Mr. Bernstein succeeds Michael Bruun in the Goldman Sachs Board seat as part of ... |
| 05.03.2025 | Parexel Announces Updates to Board of Directors | Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs Healthcare Private Equity Investing, joins as new Director.
Mr. Bernstein succeeds Michael Bruun in the Goldman Sachs Board seat as part of ... |
| 04.03.2025 | Syner-G BioPharma Group & Sequoia Biotech Consulting appoint Chris Erickson as Chief Operating Officer | Sequoia Biotech Consulting & Syner-G BioPharma Group
Industry veteran brings decades of experience to drive operational excellence
BOSTON, March 4, 2025 /PRNewswire-PRWeb/ -- Syner-G BioPharma Group (Syner-G) & Sequoia Biotech Consu... |
| 01.03.2025 | Navigating the Future: Southeast Asia's Rise in Social Impact and Study Startup Strategies | Southeast Asia is a vibrant tapestry of cultures, economies, and challenges. As the region accelerates towards becoming a powerhouse in social development and impact investing, it faces hurdles that require innovative solutions. Concurrentl... |
| 24.02.2025 | Site-Centric Strategies to Fast-Track Study Startup, Upcoming Webinar Hosted by Xtalks | www.advarra.com
In this free webinar, learn how to improve collaboration between study teams and sites to accelerate study startup. The presenters will discuss site-centric approaches to activation that reduce administrative burden, enrollm... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals
Former Karuna CFO Brown brings more than... |
| 12.03.2024 | Global Clinical Trial Kits Market Report Reveals Robust 8.57% CAGR up to 2034; Asia-Pacific Region Projected to Accelerate at Fastest Rate | - |
| 12.03.2024 | Real World Evidence/RWE Solutions Market is growing at a CAGR of 13.8% from 2024 to 2030 by Exactitude Consultancy | Real World Evidence (RWE) Solutions market
The Exactitude Consultancy Real World Evidence/RWE Solutions Market Report – Size, Trends, and Forecast 2024-2030
The Real World Evidence (RWE) Solutions market is experiencing high demand due to i... |
| 11.03.2024 | Patient Recruitment and Retention Services Global Market Report 2024 | - |
| 07.03.2024 | Oncology-Based In-Vivo CRO Market Projected for Vigorous Growth, North America Leads Regional Shares | - |
| 17.08.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 17th August 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 16.08.2023 | Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development | Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Parexel, one of the world’s largest clinical researc... |
| 11.05.2023 | Moving Cell and Gene Therapy Trials into the Community: Challenges and Opportunities, Upcoming Webinar Hosted by Xtalks | Learn practical guidance and actionable insight for addressing the complexity of study start-up and execution outside the traditional cell and gene therapy sites.
TORONTO (PRWEB) May 11, 2023
Thanks to scientific advances and resource inves... |
| 16.02.2023 | Integrated Perspectives for Enhanced Rare Disease Drug Development, Upcoming Webinar Hosted by Xtalks | Learn how a patient-first approach can be implemented through all stages of therapy development.
TORONTO (PRWEB) February 16, 2023
When rare is not so rare; more than 400 million people globally are affected by 10,000 distinct rare diseases... |
| 14.10.2022 | Parexel Recognized by Frost & Sullivan with 2022 Global Customer Value Leadership Award | The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
SAN ANTONIO, Oct. 14, 2022 /PRNewswire/ -- Based on its ... |
| 04.02.2022 | Medidata, Parexel Expands Partnership to Enhance Decentralized Clinical Trial Delivery | What You Should Know:
– Medidata, a Dassault Systèmes company and Parexel, a global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health extends their 15-year global ... |
| 16.11.2021 | Casper turns painful even for some of its earliest startup investors | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Even if a startup takes a cut to its valuation, it’s completely possible that investors who took ... |
| 20.07.2021 | Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcomes | The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies
SANTA CLARA, Calif., July 20, 2021 /PRNewswire/ -- Based on its recent analysis of the global clinical research... |
| 06.07.2021 | Down but not out: FDA rejects Provention's diabetes drug as commercial product differs from trial drug | In an expected and resolvable setback for Provention Bio, the FDA on Tuesday issued a complete response letter for the company’s Type 1 diabetes drug teplizumab after finding the commercial product failed to show pharm... |
| 06.07.2021 | What to know about Nextdoor as it goes public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Why universities should think beyond the degree From 2U
Nextdoor hit national headli... |
| 06.07.2021 | After delay caused by Italian CDMO, Novartis moves manufacturing to Austrian site | After the FDA handed Novartis a complete response letter for its PCSK9 drug inclisiran in December due to manufacturing deficiencies with its Italian CDMO partner, the company has resubmitted its application af... |
| 06.07.2021 | Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown | The major market for chronic heart failure — until recently an indication without a single approved therapy — has evolved into a horse race in recent months with some big-name drugmakers in the lead. A few steps behind N... |
| 06.07.2021 | What to know about Nextdoor as it goes public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Nextdoor hit national headlines early in the pandemic as supply shortages turned the hyper-local ... |
| 02.07.2021 | A gene therapy to restore damaged tissue after a heart attack clears pigs | How is the US going to restrict the use of Biogen’s new Alzheimer’s drug so Medicare doesn’t go bankrupt before the end of the decade? That’s the multi-billion dollar question that the federal government, payers, and clinicians will need to... |
| 02.07.2021 | A gene therapy to restore damaged tissue after a heart attack clears pigs | When GlaxoSmithKline R&D chief Hal Barron outlined his vision for the new GSK, he touted repeatedly how, digging through functional genomic datasets from partners like 23andMe and the UK Biobank, his team could see things that others ca... |
| 02.07.2021 | A gene therapy to restore damaged tissue after a heart attack clears pigs | The Covid-19 pandemic has kicked the contract research field into high gear, with a particular focus on decentralized trials as the research tool of the future. With so much work — and cash — flying around, some deep-pocketed investors are ... |
| 02.07.2021 | A gene therapy to restore damaged tissue after a heart attack clears pigs | James Martin had been trying to manipulate a particular gene to regrow heart and bone cells for six years when, while brainstorming for a grant one day in 2009, he stumbled on an old fruit fly study out of Albert Einstein Med... |
| 02.07.2021 | CureVac gains COO and hands Florian von der Mülbe new assignment in the midst of Covid-19 vaccine troubles; As Ken Frazier retires, Merck hires chief strategy officer | Malte Greune
→ Aiming to bounce back and trying to accentuate the positive after its mRNA Covid-19 vaccine took a major pratfall, CureVac is shaking things up by bringing in Malte Greune as COO and giving new responsibi... |
| 02.07.2021 | A gene therapy to restore damaged tissue after a heart attack clears pigs | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 02.07.2021 | Sartorius buys majority stake in German manufacturing player; Cerevel Therapeutics ends the week on a high note, with $350M raise | Sartorius Stedim Biotech acquired a majority stake in Germany-based CellGenix GmbH, the companies announced Friday.
Sartorius has acquired 51% of the company for $118.3 million and announced the plan to acquire the re... |
| 02.07.2021 | A gene therapy to restore damaged tissue after a heart attack clears pigs | Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its... |
| 02.07.2021 | The class of molecules behind one of biotech's biggest Alzheimer's failures gets a new lease on life | Denovo Biopharma has spent the last decade trying to resurrect drugs that failed at other companies, but it had never waded into a class of molecules that failed quite as spectacularly as 5HT6 serotonin, an oft-failed s... |
| 02.07.2021 | Covid-19 roundup: Zydus Cadila submits 3-dose vaccine for regulatory approval; US donates Moderna jabs to Pakistan during shortage | India’s second home-grown vaccine could be approved by regulators soon as Zydus Cadila announced Thursday it has applied for emergency use approval with regulators in that nation.
The jab has demonstrated efficacy of ... |
| 02.07.2021 | Busy IPO week winds down as two more biotechs — and one looking to improve clinical trials — file for public debuts | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Two more biotech companies — and one that’s committed to supporting clinical research — filed for IPOs jus... |
| 02.07.2021 | Evotec expands presence in Italy with acquisition of former GlaxoSmithKline R&D site | Germany-based Evotec established its presence in Italy four years ago. Now, it’s bought up more real estate in the neighborhood.
Evotec has acquired an R&D site in Verona from GSK, the company announced Thursday. The compa... |
| 01.07.2021 | Merck to withdraw dangling accelerated approval for Keytruda in third-line stomach cancer | In a first for the dangling accelerated approvals reviewed by FDA’s oncology adcomm in April, Merck on Thursday afternoon agreed to pull a third-line stomach cancer indication for its blockbuster Keytruda after late-s... |
| 01.07.2021 | Covid-19 manufacturing roundup: India starts manufacturing of Novavax vaccine — report; US ships spare shots to Colombia | As India’s second wave of Covid-19 infections continues to trend downward and scientists warn of a third wave of the pandemic that could lead to between 200,000 and 500,000 new cases a day, the Serum Institute of India (SII)... |
| 15.04.2021 | Veeva : Parexel and Veeva Partner to Accelerate Clinical Trials | DURHAM, N.C. and PLEASANTON, Calif., April 15, 2021 /PRNewswire/ -- Parexel and Veeva Systems (NYSE: VEEV) today announced a strategic collaboration to accelerate clinical trials through technology and process innovation. The unique collabo... |
| 10.12.2020 | What’s coming up at MedCity INVEST Precision Medicine Day 3? | The MedCity INVEST Precision Medicine healthcare conference on December 9-11 draws healthcare and life science executives and investors as we spotlight progress in the development of diagnostics, clinical trial innovation, AI in drug develo... |
| 08.12.2020 | 2020 Pediatric Perceptions & Insights Study Yields Important Insights on How to Enhance Pediatric Clinical Trial Participation | “Understanding patient health journeys and study volunteer experiences is critical to designing more patient-friendly trials that ultimately enhance pediatric patient participation,” said Ken Getz, Founder and Chairman at CISCRP.
BOSTON (PR... |
| 21.04.2020 | Initiative hopes to accelerate diagnostics and treatment for COVID-19 | Medable Inc., the digital trial platform company based in Palo Alto, CA, has introduced a way to let Americans “do more from home” to power leading research in immunity, treatments, and vaccines for COVID-19, it said. More about Innovation
... |
| 07.01.2019 | PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively | BOSTON, January 7, 2019 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and c... |
| 31.10.2018 | PAREXEL Navigates China's Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service | BOSTON, October 31, 2018 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that the Company has launched a new China Advisory Service to help global biopharmaceutical companies pa... |
| 09.10.2018 | PAREXEL Announces Several New Patient-Centric Innovations to Address Drug Development Challenges | Solutions Built on the Perceptive Cloud Platform Leverage Mobile and Wearable Technology
BOSTON, October 9, 2018 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that it has deve... |
| 11.09.2018 | PAREXEL Advances Patient-Centric Drug Development with Introduction of its Patient Innovation Center | BOSTON, September 11, 2018 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to impro... |
| 17.08.2018 | PAREXEL Announces Appointment of Two Key Executives | BOSTON, August 17, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced the appointment of Greg Rush as Executive Vice President and Chief Financial Officer and Michele Fourn... |
| 26.04.2018 | PAREXEL Announces Appointment of Peyton Howell as Chief Commercial and Strategy Officer | Proven Healthcare Industry Leader will head PAREXEL’s Commercial Strategy
BOSTON, April 26, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced the appointment of Peyton How... |
| 21.03.2018 | PAREXEL Introduces Integrated Medical Writing Solutions Service Offering | Comprehensive end-to-end services enable effective, streamlined communication with key stakeholders across all stages of drug development and commercialization
BOSTON, March 21, 2018 – PAREXEL International Corporation, the world’s leading ... |
| 13.03.2018 | PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea | Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development
BOSTON, March 13, 2018 – PAREXEL International Corporation, the world’s leading innovator of biop... |
| 06.03.2018 | PAREXEL Appoints Jamie Macdonald as Chief Executive Officer | Company Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board
BOSTON, March 6, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today ann... |
| 12.02.2018 | PAREXEL Introduces Biological Sample Lifecycle Management Service to Address Growing Demand Across Drug Development | Solution combines global laboratory logistics expertise with leading sample tracking software to optimize the management and care of human biological samples throughout their lifecycle
BOSTON, February 12, 2018 – PAREXEL International Corpo... |
| 18.12.2017 | PAREXEL Announces Enhanced Global Data Operations Offering to Drive Efficiencies for Life Science Companies | Solution now features Clinical Metadata Repository to meet evolving data standards while providing seamless and more timely workflow for clients from data collection, through analysis to submission
BOSTON, December 18, 2017 – PAREXEL Intern... |
| 15.11.2017 | PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry | New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to Market
BOSTON, November 15, 2017 — PAREXEL, a leading global biopharmaceutical services provider, today announced the appo... |
| 27.10.2017 | PAREXEL Enhances Its Active Tracking Service with Bluetooth Capability to Improve Monitoring of Temperature-Controlled Medication | Market-first feature leverages mobile and sensor technology via PAREXEL’s ClinPhone® RTSM mobile app to prevent temperature-compromised medication from reaching clinical trial patients
BOSTON, October 27, 2017 – PAREXEL International Corpor... |
| 24.10.2017 | Microsoft and PAREXEL form cloud technology alliance aimed at accelerating the pace of drug development | Companies seek to drive digital transformation of the biopharmaceutical industry by combining PAREXEL’s drug development expertise with Microsoft Azure.
REDMOND, Wash., and BOSTON — Oct. 24, 2017 — Microsoft Corp. and PAREXEL International ... |
| 06.09.2017 | PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments | Integrated offering to be provided by new dedicated service group under PAREXEL® Access
BOSTON, September 6, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that... |
| 20.06.2017 | venture leaders Life Science 2017: Walk the investors’ talk | venture leaders Life Science 2017: Walk the investors’ talk 20.06.2017 10:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
From June 12 to 16, ten Swiss startups in Life Science rocked the Boston business and innovation hub... |
| 20.06.2017 | venture leaders Life Science 2017: Walk the investors’ talk | Monday: Rolling the pitch
PAREXEL, 7:30AM. A short night after landing at Logan airport, the participants went to PAREXEL in a school bus. The day started with a presentation by CEO Josef H. von Rickenbach. PAREXEL actually started as a sta... |
| 20.06.2017 | Term Sheet — Tuesday, June 20 | “I GOT A FEELING I’M OFF SCRIPT”
NEW MONEY + NEW PRODUCT: Managed by Q, a New York City-based on-demand office services startup, has launched a marketplace for its office management products, offering self-service cleaning, plumbing, electr... |
| 19.06.2017 | PAREXEL introduces its Connected Journey™ of newly integrated data-driven services to simplify drug development and commercialisation | Features new ForeSite™ clinical trial methodology designed to reliably predict site success
LONDON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficie... |
| 09.05.2017 | Term Sheet — Tuesday, May 9 | PROFITABILITY OVER PASSION
Land of Opportunity: Yesterday’s Term Sheet included a link to this story about SoftBank’s ambitions in India that deserves a little more attention. Like so many articles about tech in India, this one draws compar... |
| 30.03.2017 | PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection | Comprehensive wearables and sensors solution, powered by the Perceptive MyTrials® Analytics platform, creates greater efficiencies for biopharmaceutical companies
LONDON, March 30, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a ... |
| 28.02.2017 | PAREXEL International appoints Simon Harford as Senior Vice President and Chief Financial Officer | Appointment Effective June 1, 2017
LONDON, February 28, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President... |
| 13.02.2017 | PAREXEL Launches ClinPhone RTSM Mobile App to Improve Supply Management and Increase Patient Safety | LONDON, February 13, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone® RTSM (randomisation and trial supply management) service. The... |
| 02.02.2017 | PAREXEL Announces Definitive Agreement to Acquire The Medical Affairs Company | Acquisition will strengthen and add scale to current commercialisation and medical affairs services
LONDON, February 2, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today ann... |
| 14.11.2016 | PAREXEL Launches IDMP-Focused Software And Service Solution | Solution developed to help biopharmaceutical companies meet emerging regulatory requirements ahead of deadline
LONDON, November 14, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provide... |
| 01.08.2016 | PAREXEL Appoints Four Executives to Senior Leadership Team | BOSTON, August 1, 2016 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of four company executives to its senior-most leadership team, the Business Rev... |
| 18.12.2015 | PAREXEL Wins Best Technological Development In Clinical Trial Award At The 11th Annual Scrip Awards | LONDON, December 18, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that its Country Allocation Technology won the Best Technological Development in Clinical Tr... |
| 15.12.2015 | PAREXEL Informatics President Named A 2016 Computerworld Premier 100 Technology Leader | LONDON, December 15, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced that IDG’s Computerworld named Xavier Flinois, President, PAREXEL Informatics, a 2016 Premier 100 ... |
| 01.12.2015 | PAREXEL Launches IMPACT® Express Clinical Trial Management System | London, 1 December, 2015 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today introduced IMPACT® Express Clinical Trial Management System (CTMS). IMPACT Express provides a quick-to-... |
| 21.07.2015 | PAREXEL Launches Next Generation Analytics Capabilities Within Perceptive MyTrials® Platform | Enhancements offer clients cross-study oversight through mobile-enabled reporting and analysis
London, UK, July 21, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launche... |
| 09.07.2015 | PAREXEL Expands Model-Based Drug Development Offering | London, July 9, 2015 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced expanded services and capabilities in model-based drug development (MBDD) through their Quantitat... |
| 18.06.2015 | PAREXEL Launches Next Generation Data-Driven Monitoring Capabilities Within Perceptive MyTrials® Solution | Enhancements offer clients increased clinical trial efficacy and seamless data-driven monitoring experience
London, UK, June 18, 2015 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, ... |
| 08.04.2015 | PAREXEL stärkt sein globales Engagement in der Aus- und Weiterbildung in der Klinischen Forschung mit neuen Studiengängen an der PAREXEL Academy und ihren Kooperationspartnern | Studiengang: Bachelor of Science in Clinical Research in Deutschland
Postgraduate-Certificate in Clinical Trial Management in Boston, MA.
Studiengang Bachelor of Science in Pharmacology, Modul Einführung in die Klinische Forschung in Japan
... |
| 08.04.2015 | PAREXEL Strengthens Commitment To Global Biopharmaceutical Workforce With New PAREXEL Academy Programmes | Bachelor of Science Degree in Clinical Research offered in Europe
Postgraduate Certificate in Clinical Trial Management offered in North America
Joint Programme for Clinical Research and Clinical Trial Management offered in Asia
London, UK ... |
| 31.03.2015 | PAREXEL Launches LIQUENT InSight® 6.0 Regulatory Information Management Platform | London, 31 March, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6... |
| 18.02.2015 | PAREXEL Simplifies Patient Recruitment And Study Start-Up Timelines Through Innovative Site Alliance Network | Global network accelerates patient recruitment and clinical trial start-up times
London, UK, 18 February 2015 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the cont... |
| 15.12.2014 | PAREXEL ClinPhone® RTSM Named Leader Of Interactive Response Technology In New Benchmark Report From Industry Standard Research | London, UK, 15 December 2014 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its randomisation and trial supply management (RTSM) services, ClinPhone® RTSM, rank... |
| 03.10.2014 | PAREXEL International Announces Acquisition Of ClinIntel, Extending Leadership In Randomisation And Trial Supply Management | London, UK, October 3, 2014 - PAREXEL International Corporation (Nasdaq: PRXL)("PAREXEL" or the "Company"), a global clinical research organisation, announced today that the Company has acquired all of the outstanding eq... |
| 02.07.2014 | PAREXEL International Announces Acquisition Of ATLAS Medical Services, A Provider Of Clinical Research Services In Turkey | London, UK, July 2, 2014 – PAREXEL International Corporation (Nasdaq: PRXL)(“PAREXEL” or the “Company”), a global clinical research organisation, announced today that the Company has acquired all of the outstanding equity securities of ATLA... |
| 16.06.2014 | PAREXEL Cuts Clinical Trial Start-Up Time For Sponsors By Weeks With New Version Of Industry-Leading ClinPhone® RTSM Services | Latest RTSM technology features standardized study components for faster implementation and greater design flexibility
London, 16 June, 2014 – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, t... |
| 27.05.2014 | PAREXEL Names Dr. Sy Pretorius Chief Scientific Officer | To lead integration of Company’s global scientific expertise and services to meet end-to-end customer drug development needs
LONDON, UK, 27 May, 2014 – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organi... |
| 20.05.2014 | PAREXEL Launches Perceptive MyTrials® Data-Driven Monitoring To Increase Patient Safety And Reduce Clinical Trial Costs | Technology solution designed to improve monitoring effectiveness and efficiency
LONDON, UK, 20th May, 2014 – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced the launch of its P... |
| 27.12.2012 | CRO’s $72M software acquisition boosts its informatics muscle | “We are solving many of the problems for our space that eventually need to be solved for the broader health care world… Most clinical trials have multiple technologies now involved. For instance, another technology of note would be the rand... |
| 23.04.2012 | What Dennis Gillings told me about Quintiles during a chance encounter | “Oh, we’re dead in the water, I’m afraid,” he deadpanned.
Far from it. The company that Gillings launched in 1982 has grown to become the largest CRO in the industry with annual revenue of more than $3 billion. But there may have been occas... |
| 01.03.2012 | INC Research tops CRO quality ranking as M&A shapes pharma outsourcing | Before acquiring Kendle last year, INC was a mid-sized CRO whose size and pharmaceutical outsourcing service offerings fell well short of the largest CROs such as Quintiles and Parexel. Raleigh, North Carolina-based INC’s service quality me... |
| 23.12.2011 | A clinical research organization wish list for Christmas (and new year) | A strategic partner: The biggest CROs such as, Quintiles, PPD, and Covance (NYSE:CVD) are increasingly moving toward strategic partnerships, making them a “preferred provider” of services. In these arrangements, a pharma will contract with ... |
| 14.06.2011 | Mid-sized CROs perform as good or better than larger ones, survey says | Kevin Olson, CEO of ISR, said that the survey responses and data do not show why mid-sized CROs as a whole scored better than larger ones. But he theorizes the smaller CROs might be seen as offering better service because while they may not... |
| 05.10.2010 | Parexel opens another office in Japan | Parexel International Corp. (NSDQ:PRXL) brought the number of its offices in Japan to three with the addition of a new office in Nagoya.
The Waltham, Mass.-based clinical research organization established the new location to prop up its cli... |
| 10.08.2010 | Parexel International ends fiscal 2010 in the black | Parexel International Corp. (NSDQ:PRXL) wrapped up its fiscal 2010 reporting a 19.4 percent increase in overall sales and adjusted net earnings of $19.1 million.
The 32-cent per share adjusted profit — which excludes just under $10 million ... |
| 26.01.2010 | Q2 less than perfect for Parexel | Restructuring costs cut deeply into second-quarter profits at Parexel International Corp. (NSDQ:PRXL) during the three months ended Dec. 31, with severance and related expenses costing the clinical research organization $14.3 million during... |
| - | What Dennis Gillings told me about Quintiles during a chance encounter | Dennis Gillings doesn’t give many interviews and today, the day his Quintiles successor was announced, he wasn’t available to talk either.
I’ve had a few occasions to talk with Gillings and our most recent exchange happened after a life sci... |
| - | INC Research tops CRO quality ranking as M&A shapes pharma outsourcing | Among clinical research organizations, INC Research is not the biggest, but by at least one measure, it stands out as the best.
INC received the best service quality scores in the annual CRO quality benchmarking study conducted by Industry ... |
| - | Mid-sized CROs perform as good or better than larger ones, survey says | Pharmaceutical companies evaluating which clinical research organizations to work with might want to take note that perhaps size doesn’t matter.
As a group, mid-sized CROs performed quite well or even better than their larger counterparts a... |
| - | The evolution of functional service provider (FSP) models | Clinical development outsourcing is evolving. While functional service provider (FSP) models have been around for more than 20 years, today’s strategies bear little resemblance to their early counterparts. Originating as staff augmentation ... |
